Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.

Guo D, Xu Q, Pabla S, Koomen J, Biddinger P, Sharma A, Pabla S, Pacholczyk R, Chang CC, Friedrich K, Mohammed K, Smallridge RC, Copland JA, She JX, Weinberger PM.

Int J Mol Sci. 2018 Feb 14;19(2). pii: E577. doi: 10.3390/ijms19020577.

2.

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.

Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4506-4514. doi: 10.1210/jc.2017-01180.

PMID:
29029287
3.

Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma.

Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW.

Rare Tumors. 2017 Sep 15;9(2):6834. doi: 10.4081/rt.2017.6834. eCollection 2017 Jul 3.

4.

ACTIVE SURVEILLANCE FOR PAPILLARY THYROID MICROCARCINOMA: NEW CHALLENGES AND OPPORTUNITIES FOR THE HEALTH CARE SYSTEM.

Haser GC, Tuttle RM, Su HK, Alon EE, Bergman D, Bernet V, Brett E, Cobin R, Dewey EH, Doherty G, Dos Reis LL, Harris J, Klopper J, Lee SL, Levine RA, Lepore SJ, Likhterov I, Lupo MA, Machac J, Mechanick JI, Mehra S, Milas M, Orloff LA, Randolph G, Revenson TA, Roberts KJ, Ross DS, Rowe ME, Smallridge RC, Terris D, Tufano RP, Urken ML.

Endocr Pract. 2016 May;22(5):602-11. doi: 10.4158/EP151065.RA. Epub 2016 Jan 22. Review.

5.

A Century of Hyperthyroidism at Mayo Clinic.

Smallridge RC, Morris JC.

Mayo Clin Proc. 2016 Jan;91(1):e7-e12. doi: 10.1016/j.mayocp.2015.09.016. Epub 2015 Nov 18. No abstract available.

PMID:
26602598
6.

Anaplastic Thyroid Carcinoma, Version 2.2015.

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50.

7.

RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.

Marlow LA, Bok I, Smallridge RC, Copland JA.

Endocr Relat Cancer. 2015 Oct;22(5):777-92. doi: 10.1530/ERC-14-0302. Epub 2015 Jul 23.

8.

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E.

Oncotarget. 2015 Apr 20;6(11):9073-85.

9.

Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2015 May;100(5):E697-709. doi: 10.1210/jc.2014-2764. Epub 2015 Feb 12.

10.

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

Kasaian K, Chindris AM, Wiseman SM, Mungall KL, Zeng T, Tse K, Schein JE, Rivera M, Necela BM, Kachergus JM, Casler JD, Mungall AJ, Moore RA, Marra MA, Copland JA, Thompson EA, Smallridge RC, Jones SJ.

J Clin Endocrinol Metab. 2015 Apr;100(4):E611-5. doi: 10.1210/jc.2014-3622. Epub 2015 Jan 27.

11.

miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, He M, Davis S, Dreiling J, Copland JA, Smallridge RC, Quezado MM, Kebebew E.

Cancer Res. 2015 Jan 15;75(2):367-77. doi: 10.1158/0008-5472.CAN-14-2304. Epub 2014 Dec 8.

12.

S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.

Reeb AN, Li W, Sewell W, Marlow LA, Tun HW, Smallridge RC, Copland JA, Spradling K, Chernock R, Lin RY.

J Clin Endocrinol Metab. 2015 Feb;100(2):E232-42. doi: 10.1210/jc.2014-2988. Epub 2014 Nov 25.

13.

Clinical and molecular features of Hürthle cell carcinoma of the thyroid.

Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, Necela BM, Hay ID, Westphal SA, Grant CS, Thompson GB, Schlinkert RT, Thompson EA, Smallridge RC.

J Clin Endocrinol Metab. 2015 Jan;100(1):55-62. doi: 10.1210/jc.2014-1634.

PMID:
25259908
14.
15.
16.

What is the gold standard for comprehensive interinstitutional communication of perioperative information for thyroid cancer patients? A comparison of existing electronic health records with the current American Thyroid Association recommendations.

Dos Reis LL, Tuttle RM, Alon E, Bergman DA, Bernet V, Brett EM, Cobin R, Doherty G, Harris JR, Klopper J, Lee SL, Lupo M, Milas M, Machac J, Mechanick JI, Orloff L, Randolph G, Ross DS, Smallridge RC, Terris DJ, Tufano RP, Mehra S, Scherl S, Clain JB, Urken ML.

Thyroid. 2014 Oct;24(10):1466-72. doi: 10.1089/thy.2014.0209. Epub 2014 Sep 5. Review.

PMID:
25036190
17.

Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass.

Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC.

J Clin Oncol. 2015 Jun 10;33(17):e74-6. doi: 10.1200/JCO.2013.49.3213. Epub 2014 Mar 24. No abstract available.

PMID:
24663046
18.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium.

J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.

19.

Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative.

Urken ML, Milas M, Randolph GW, Tufano R, Bergman D, Bernet V, Brett EM, Brierley JD, Cobin R, Doherty G, Klopper J, Lee S, Machac J, Mechanick JI, Orloff LA, Ross D, Smallridge RC, Terris DJ, Clain JB, Tuttle M.

Head Neck. 2015 Apr;37(4):605-14. doi: 10.1002/hed.23615. Epub 2014 Apr 3.

PMID:
24436291
20.

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela BM, Eberhardt NL, Carr JM, McIver B, Copland JA, Thompson EA.

J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792. Epub 2013 Dec 2.

21.

Airway issues in anaplastic thyroid carcinoma.

Shaha AR, Ferlito A, Owen RP, Silver CE, Rodrigo JP, Haigentz M Jr, Mendenhall WM, Rinaldo A, Smallridge RC.

Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2579-83. doi: 10.1007/s00405-013-2556-3. Epub 2013 May 21. No abstract available.

PMID:
23689802
22.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.

23.

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC.

Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.

24.

Effect of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence.

Tan WW, Heckman MG, Vishnu P, Crook JE, Younkin LH, Covil EG, Ferman TJ, Graff-Radford NR, Younkin SG, Smallridge RC, Wehle MJ, Buskirk SJ.

Urology. 2013 Jan;81(1):150-4. doi: 10.1016/j.urology.2012.08.066.

PMID:
23273081
25.

American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce.

Thyroid. 2012 Nov;22(11):1104-39. doi: 10.1089/thy.2012.0302.

PMID:
23130564
26.

An uncommon cause of asymptomatic primary hyperparathyroidism.

Abate EG, Bernet V, May GR, Smallridge RC.

J Clin Endocrinol Metab. 2012 Dec;97(12):4304-5. doi: 10.1210/jc.2012-2419. Epub 2012 Sep 19. No abstract available.

PMID:
22993031
27.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

J Oncol Pract. 2012 May;8(3 Suppl):e1s-5s. doi: 10.1200/JOP.2011.000496.

28.

Approach to the patient with anaplastic thyroid carcinoma.

Smallridge RC.

J Clin Endocrinol Metab. 2012 Aug;97(8):2566-72. doi: 10.1210/jc.2012-1314.

29.

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C; Mayo Phase 2 Consortium; Mayo Clinic Endocrine Malignances Disease Oriented Group.

J Clin Endocrinol Metab. 2012 Sep;97(9):3179-84. Epub 2012 Jul 6.

30.

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428. Epub 2012 Jun 20.

31.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

Am J Manag Care. 2012 May 1;18(5):e162-7.

32.

Toward improved outcomes in patients with anaplastic thyroid cancer.

Bible KC, Foote RL, Smallridge RC.

Oncology (Williston Park). 2012 Apr;26(4):398, 401, 406. No abstract available.

33.

Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.

Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC.

J Clin Endocrinol Metab. 2012 Aug;97(8):2714-23. doi: 10.1210/jc.2011-3017. Epub 2012 May 25.

PMID:
22639286
34.

Systemic therapeutic approaches to advanced thyroid cancers.

Menefee ME, Smallridge RC, Bible KC.

Am Soc Clin Oncol Educ Book. 2012:389-92. doi: 10.14694/EdBook_AM.2012.32.389.

35.

Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.

Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC.

Thyroid. 2011 Jan;21(1):25-30. doi: 10.1089/thy.2010.0220. Epub 2010 Dec 16.

PMID:
21162687
36.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium.

Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17.

37.

Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.

Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2010 Dec;95(12):5338-47. doi: 10.1210/jc.2010-1421. Epub 2010 Sep 1. Erratum in: J Clin Endocrinol Metab. 2013 Oct;98(10):4213. J Clin Endocrinol Metab. 2013 Nov;98(11):4546.

38.

Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Smallridge RC, Copland JA.

Clin Oncol (R Coll Radiol). 2010 Aug;22(6):486-97. doi: 10.1016/j.clon.2010.03.013. Epub 2010 Apr 24. Review.

39.

Hormonal and cardiovascular response to low-intensity exercise with atropine administration.

Kamimori GH, Bellar D, Fein HG, Smallridge RC.

Mil Med. 2009 Mar;174(3):253-8.

PMID:
19354088
40.

Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA.

Cancer Res. 2009 Feb 15;69(4):1536-44. doi: 10.1158/0008-5472.CAN-08-3718. Epub 2009 Feb 10.

41.

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Smallridge RC, Marlow LA, Copland JA.

Endocr Relat Cancer. 2009 Mar;16(1):17-44. doi: 10.1677/ERC-08-0154. Epub 2008 Nov 5. Review.

42.

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR.

J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41. doi: 10.1210/jc.2008-1102. Epub 2008 Aug 19.

43.

Disparities in participation in cancer clinical trials in the United States : a symptom of a healthcare system in crisis.

Colon-Otero G, Smallridge RC, Solberg LA Jr, Keith TD, Woodward TA, Willis FB, Dunn AN.

Cancer. 2008 Feb 1;112(3):447-54.

44.
45.

Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.

Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP.

J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8. Epub 2007 Jul 31.

PMID:
17666472
46.

Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases.

Copland JA, Marlow LA, Williams SF, Grebe SK, Gumz ML, Maples WJ, Silverman VE, Smallridge RC.

Thyroid. 2006 Dec;16(12):1293-302.

PMID:
17199440
47.

Thyroid autoimmunity and breast cancer--cause or effect?

Smallridge RC.

Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):660-1. No abstract available.

PMID:
17143309
48.

Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.

Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, Fatourechi V.

J Clin Endocrinol Metab. 2007 Jan;92(1):82-7. Epub 2006 Oct 31.

PMID:
17077133
50.

Prevalence of postpartum thyroid dysfunction: a quantitative review.

Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR.

Thyroid. 2006 Jun;16(6):573-82. Review.

PMID:
16839259

Supplemental Content

Loading ...
Support Center